Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 16;128(8):1122-1138.
doi: 10.1161/CIRCRESAHA.120.317914. Epub 2021 Feb 17.

miR-33 Silencing Reprograms the Immune Cell Landscape in Atherosclerotic Plaques

Affiliations

miR-33 Silencing Reprograms the Immune Cell Landscape in Atherosclerotic Plaques

Milessa Silva Afonso et al. Circ Res. .

Abstract

[Figure: see text].

Keywords: adaptive immunity; atherosclerosis; inflammation; macrophages; microRNA.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Inhibition of miR-33 induces atherosclerosis regression by reducing the plaque macrophage content.
A) Experimental outline: Atherosclerosis was established in Ldlr−/− mice by feeding a western diet for 14 weeks (baseline), after which mice were treated with control anti-miR or anti-miR-33 for 4 weeks on chow diet. Monocyte labeling was performed at baseline to macrophage retention, or 3 days prior to the end of the treatment period to assess monocyte recruitment. B-C) Plasma levels of (B) total cholesterol (TC) and HDL cholesterol and (C) triglycerides (TG), (n=7 baseline, 15 control anti-miR and 15 anti-miR-33). D-E) Quantification of atherosclerotic lesion area in (D) cross-sections of the aortic root (Scale bar = 250 μm) (n= 6 baseline, 12 control anti-miR and 12 anti-miR-33) and (E) the aorta en face (n= 5 mice/group). F-G) Quantification of plaque macrophage content measured by (F) CD68 immunostaining of the aortic root (Scale bar = 250 μm) (n= 6 baseline, 10 control anti-miR and 12 anti-miR-33) and (G) flow cytometric analysis of F4/80 in the aortic arch (n= 9 baseline, 10 control anti-miR and 10 anti-miR-33). Representative images were selected to represent the mean value of each condition. (B-G) Data are the mean ± S.E.M. P values were determined by (B, D) one-way ANOVA with post-hoc Tukey’s test, (E) Mann-Whitney U-test or (C, F, G) Kruskal-Wallis with post-hoc Dunn’s test.
Figure 2.
Figure 2.. Single cell RNA-sequencing reveals that miR-33 inhibition alters the immune cell landscape in plaques.
A) t-Stochastic neighbor embedding (t-SNE) plot showing clustering of aortic arch CD45+ cells based on gene expression. B) Immune cell frequencies in the aortic arches of mice treated with anti-miR-33 or control anti-miR. C) Frequency of the 3 macrophage clusters identified by single cell RNA-sequencing of CD45+ cells from the aortic arches of mice treated with anti-miR-33 or control anti-miR. D) Circos plots showing genome-wide differential expression of miR-33 target genes in each of the macrophage clusters. The inner track shows predicted miR-33 target genes that are upregulated (red arcs) or downregulated (blue arcs) in anti-miR-33 vs control anti-miR treatment. The outer track shows the chromosomal location of the miR-33 target genes. Data in A-D are from n=4 mice pooled/group; anti-miR-33 and control anti-miR.
Figure 3.
Figure 3.. Inhibition of miR-33 decreases monocytosis and extramedullary hematopoiesis in the spleen.
A) Blood levels of monocytes in Ldlr−/− mice fed chow diet, western diet for 14 weeks (Baseline), or after treatment with anti-miR-33 or control anti-miR for 4 weeks. n=7 chow diet, 8 baseline, 16 control anti-miR, 15 anti-miR-33. B) Flow cytometric analysis of Ly6Chi and Ly6Clo monocytes in the blood of atherosclerotic Ldlr−/− mice treated with anti-miR-33 (n=15) or control anti-miR (n=14). C) Flow cytometric analysis of bone marrow hematopoietic stem and progenitor cell populations (LSK, LinSca+Kit cells; CMP, common myeloid progenitor; GMP, granulocyte-myeloid progenitor, n=12 mice/group). D) Representative images and spleen weights from Ldlr−/− mice treated with anti-miR-33 or control anti-miR. n=15 mice/group. Scale 5 mm. E) Flow cytometric analysis of splenic hematopoietic stem and progenitor cell populations. n=9 control anti-miR and 10 anti-miR-33. F) Flow cytometry gating strategy for LSK, CMP and GMP cells in the bone marrow and spleen. Data in A-E are the mean ± SEM. P values were determined by Kruskal-Wallis with post-hoc Dunn’s test (A), Student’s t-test (B) or Mann-Whitney’s test (C-E). ns=not significant.
Fig 4.
Fig 4.. Inhibition of miR-33 alters monocyte-macrophage dynamics in the plaque.
A-B) Representative images and quantification of (A) Edu-labeled Ly6Chi (n=9 mice/group, scale= 100 μm) and (B) fluorescent bead-labeled Ly6Clo (n = 15 mice/group, scale = 10 μm) monocytes recruited into aortic root plaques of Ldlr−/− mice treated with anti-miR-33 or control anti-miR. C) Representative images and quantification of Ly6Chi monocyte-derived macrophages (Edu+) retained in aortic root plaques after 4 weeks of anti-miR-33 or control anti-miR treatment. Scale bar = 100 μm (n = 6/group). D) Fold change in RNA-seq reads of genes involved in macrophage migration and retention in anti-miR33 vs control anti-miR treated mice by macrophage clusters. E) Representative images and quantification of immunostaining for the proliferation marker Ki67 and the macrophage marker CD68 in aortic root plaques of Ldlr−/− mice treated with anti-miR-33 or control anti-miR. Scale bar = 100 μm (n=13/group). F) Fold change in RNA-seq reads of proliferation and inflammatory genes in anti-miR-33 versus control anti-miR treated mice within the indicated aortic macrophage populations. G) Representative images and quantification of the apoptotic cell marker TUNEL in aortic root plaques of Ldlr−/− mice treated with anti-miR-33 or control anti-miR. (n=9 mice/group, scale = 100 μm). H) Fold change in RNA-seq reads of cell death-related genes in anti-miR33 vs control anti-miR treated mice by macrophage clusters (n=4 pooled mice/group in scRNA-seq). P values were determined by Mann-Whitney’s test (A, B, C, E) or by Student’s t-test (D, F, G, H). P values in D, F and H are unadjusted and represent significantly different gene expression presented in Log2FC for anti-miR-33 as compared to control anti-miR treatment in the indicated macrophage cluster. ns=not significant.
Figure 5.
Figure 5.. Inhibition of miR-33 promotes macrophage processes associated with plaque remodeling and repair.
A) Representative images of costaining for the apoptosis marker TUNEL and the macrophage marker Mac-2, and quantification of macrophage-bound and free apoptotic cells to determine efferocytosis in aortic root plaques of Ldlr−/− mice treated with anti-miR-33 or control anti-miR (n=9 mice/group, scale = 25 μm). B) Fold change in RNA-seq reads of efferocytosis-related genes in anti-miR33 vs control anti-miR treated mice by macrophage clusters. P values were determined by Student’s t-test and represent significantly different gene expression presented in Log2FC for anti-miR-33 as compared to control anti-miR treatment in the indicated macrophage cluster. C-D) Quantification of necrotic area in hematoxylin and eosin stained aortic root plaques of mice treated with control anti-miR or anti-miR-33. Representative images shown in D. Scale bar = 250 μm. n=15 control anti-miR and 12 anti-miR-33. E) Representative images and quantification of immunostaining for the M2 macrophage marker CD206 (Mrc1) in aortic root plaques of Ldlr−/− mice treated with anti-miR-33 or control anti-miR. Scale bar = 25 μm. n=5 mice/group. Data in A, C, E are expressed as mean ± SEM. P values were determined by Mann-Whitney’s test (A, E) or Student’s t-test (D). F) Mrc1 expression in immune cells clusters identified by single cell RNA sequencing of aortic arch CD45+ cells (n=4 mice/group pooled). G-I) Top enriched canonical pathways in aortic macrophage clusters of anti-miR-33 vs control anti-miR treated mice. Significant pathways were identified based on a 5% false discovery rate using the Benjamini-Hochberg procedure (B-H p-value <0.05) within the Canonical Pathways annotations by Ingenuity Pathway Analysis. Activated canonical pathways (Z score >2) are indicated by red filled dots, while inhibited pathways (Z-score <−2) are indicated by blue filled dots. Key pathways of interest are annotated. ns=not significant.
Figure 6.
Figure 6.. Inhibition of miR-33 alters the T cell balance in atherosclerotic plaques to promote inflammation resolution.
A) NanoString immune profiling gene set analysis of RNA from aortic arches of Ldlr−/− mice treated with anti-miR-33 or control anti-miR (n=6 mice/group). B) t-Stochastic neighbor embedding (t-SNE) plot showing clustering of T cells from the aortic arch of Ldlr−/− mice treated with anti-miR-33 or control anti-miR based on gene expression. n=4 mice pooled/group. C) Frequencies of the T cell clusters identified by single cell RNA-sequencing of CD45+ cells from the aortic arches of mice treated with anti-miR-33 or control anti-miR. D-E) Flow cytometric analysis of CD8+ and CD3+ T cells (D), and CD4+ T helper cell subsets (E) in aortic arches of mice treated with control anti-miR or anti-miR-33 (n=8 baseline, 9 control anti-miR and 9 anti-miR33). Data in D-E are presented as mean ± S.E.M. P values were determined by one-way ANOVA followed by post-hoc Tukey’s test for T cells, T helper cells and regulatory T cells or Kruskal-Wallis followed by Dunn’s test for Th1, Th2 and CD8 T cells. ns=not significant.

Similar articles

Cited by

References

    1. Rhoads JP and Major AS. How Oxidized Low-Density Lipoprotein Activates Inflammatory Responses. Crit Rev Immunol. 2018;38:333–342. - PMC - PubMed
    1. Wolf D and Ley K. Immunity and Inflammation in Atherosclerosis. Circ Res. 2019;124:315–327. - PMC - PubMed
    1. Danesh J, Collins R, Appleby P and Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477–82. - PubMed
    1. Olivares R, Ducimetiere P and Claude JR. Monocyte count: a risk factor for coronary heart disease? Am J Epidemiol. 1993;137:49–53. - PubMed
    1. Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R and Pittet MJ. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest. 2007;117:195–205. - PMC - PubMed

Publication types